XNASCYTO
Market cap1mUSD
Dec 19, Last price
0.30USD
1D
-25.94%
1Q
-57.76%
Jan 2017
-100.00%
IPO
-100.00%
Name
Altamira Therapeutics Ltd
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
65.34%
Rev. gr., 5y
-1.04%
Revenues
0k
-100.00%
Net income
-7m
L-72.60%
CFO
-12m
L+32.57%
Earnings
May 16, 2025
Profile
Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It operates in Switzerland, the United States, Europe, and Australia. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda.
Valuation
Title CHF in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
| Income | ||||||||||
Revenues | 306 378.41% | 64 -63.39% | ||||||||
Cost of revenue | 6,143 | 27,025 | 17,574 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (6,143) | (26,719) | (17,510) | |||||||
NOPBT Margin | ||||||||||
Operating Taxes | (10) | 22 | ||||||||
Tax Rate | ||||||||||
NOPAT | (6,143) | (26,709) | (17,531) | |||||||
Net income | (7,270) -72.60% | (26,528) 52.55% | (17,390) 112.07% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | 100 | 5,988 | 114 | |||||||
Long-term debt | 100 | 805 | 1,037 | |||||||
Deferred revenue | 932 | |||||||||
Other long-term liabilities | 347 | 336 | 670 | |||||||
Net debt | (2,915) | 6,583 | (32) | |||||||
| Cash flow | ||||||||||
Cash from operating activities | (11,511) | (8,683) | (13,673) | |||||||
CAPEX | (2,143) | (3,326) | ||||||||
Cash from investing activities | 1,445 | (2,142) | (3,505) | |||||||
Cash from financing activities | 10,622 | 9,832 | 6,614 | |||||||
FCF | (10,901) | (22,453) | (17,063) | |||||||
| Balance | ||||||||||
Cash | 617 | 15 | 984 | |||||||
Long term investments | 2,497 | 194 | 199 | |||||||
Excess cash | 3,115 | 194 | 1,180 | |||||||
Stockholders' equity | (17,866) | (200,937) | (175,807) | |||||||
Invested Capital | 24,771 | 200,222 | 189,757 | |||||||
ROIC | ||||||||||
ROCE | 4,534.42% | |||||||||
| EV | ||||||||||
Common stock shares outstanding | 491 | 46 | 33 | |||||||
Price | 3.48 -96.41% | 97.00 -86.64% | 726.00 -30.73% | |||||||
Market cap | 1,710 -61.30% | 4,417 -81.63% | 24,042 52.58% | |||||||
EV | (1,206) | 11,000 | 24,010 | |||||||
EBITDA | (6,024) | (26,600) | (17,433) | |||||||
EV/EBITDA | 0.20 | |||||||||
Interest | 912 | 190 | ||||||||
Interest/NOPBT | ||||||||||